Ladies talking

Targeted testing for hereditary breast and ovarian cancer syndromes


BRCA1 and BRCA2 mutations account for most families with hereditary breast and ovarian cancer syndrome (HBOC),1 and the estimated lifetime risk of breast cancer in women with BRCA1 mutations is 46% to 87%; for BRCA2, the risk is 38% to 84%.2

Labcorp's BRCAssure assay 

At Labcorp, we understand the importance of identifying patients with a BRCA mutation. With the analytical sensitivity and specificity of Labcorp’ BRCAssure assay, and a comprehensive suite of tests to identify BRCA mutations associated with breast and ovarian cancer, as well as other cancers, you can have confidence in the test performance and select the BRCAssure testing option that is the most appropriate for your patient based on her or his personal or family medical history.

Estimated lifetime cancer risk for individuals with BRCA1 and BRCA2 mutations chart

Helping patients understand their results

Discussing BRCAssure testing results with patients can be a challenge in the short time you have to speak with them during an appointment. To help simplify the discussion, Labcorp is pleased to provide you with patient genetic eduational videos that provide information on the test result and the possible next steps, if any, that the patient should consider, including speaking with a genetic counselor. 

Test Options


  1. American College of Obstetricians and Gynecologists. Hereditary Breast and Ovarian Cancer Syndrome. ACOG
    Practice Bulletin. No. 182. Obstet Gynecol. 2017; Sep;130(3):e-110-e126.
  2. Petrucelli, N et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. Gene Reviews. Available at: http://www. Accessed October 27, 2021.